inxmed limited
PrivateLast Round
Series C
Aug 22, 2025
Last Round Size
$34M
Est. Valuation
$306M
Total Funding Raised
$134M
Company Overview
Developer of cancer therapeutics targeting drug resistance and the stroma microenvironment for hard-to-treat solid tumors.
Historical Pricing
Historical view of private secondary pricing and transaction trends.
inxmed limited Comparables
Compare inxmed limited with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Parthenon Therapeutics | 74% | |
| Mestag Therapeutics | 64% | |
| BroadenBio Co., Ltd. | 63% |
inxmed limited Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Aug 22, 2025 | ||||
| Series B Extension | May 8, 2022 | ||||
| Series B | Mar 3, 2022 | ||||
| Series A Extension | Sep 3, 2020 | ||||
| Series A | Dec 31, 2018 |
inxmed limited Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessSee something wrong or outdated?